XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
August 30 2021 - 9:00AM
XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the
addition of Mark Ziats, M.D. Ph.D. as Medical Director. Dr. Ziats
will be involved in developing and managing a diverse clinical
portfolio for the Company’s drug candidates. The Company is
developing novel drugs, including those to treat cardiovascular
disease, cancer, arthritis and infectious diseases. Dr. Ziats will
work with a multidisciplinary team, including key opinion leaders
in the respective fields of medicine, to facilitate clinical
development of the Company’s candidate drugs across all areas.
Dr. Ziats received his medical training in Texas from Baylor
College of Medicine in Houston; received his PhD in genetics from
the University of Cambridge, England as part of the NIH-Cambridge
Biomedical Scholars Program; and completed his residency in
Internal Medicine at the University of Michigan. Mark Ziats is
board-certified by the American Board of Internal Medicine, has
practiced broad inpatient and post-acute care medicine, and has
held the post of clinical assistant professor at the University of
South Carolina School of Medicine Greenville. Dr. Ziats has
authored research publications relating to his work in
neurodevelopment, clinical genetics and immune signaling
pathways.
John Simard, CEO of XBiotech, stated, “I am pleased to welcome
Mark to XBiotech. His intellect and energy will add strength to
XBiotech and our clinical program. The Company’s extraordinary
mission—to use the human body’s naturally occurring antibodies to
treat disease—is definitely a pursuit worthy of his talents.”
Mark Ziats commented, “I am very excited to join the team at
XBiotech, as they have already shown the impact that True Human
antibody therapeutics can have, and I believe this important and
novel technology can be developed further to improve the lives of
many patients across a wide spectrum of disorders.”
About True Human™ Therapeutic
AntibodiesXBiotech’s True Human™ antibodies are derived
without modification from individuals who possess natural immunity
to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech’s True Human™ antibodies have the
potential to harness the body’s natural immunity to fight disease
with increased safety, efficacy and tolerability.
About XBiotech XBiotech
is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of
therapeutic antibodies based on its True Human™ proprietary
technology. XBiotech currently is advancing a robust pipeline of
antibody therapies to redefine the standards of care in oncology,
inflammatory conditions and infectious diseases. Headquartered in
Austin, Texas, XBiotech is also leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce therapies urgently
needed by patients worldwide. For more information, visit
www.xbiotech.com.
Cautionary Note on Forward-Looking
Statements This press release
contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve
substantial risks and uncertainties. In some cases, you can
identify forward-looking statements by terminology such as "may,"
"will," "should," "would," "could," "expects," "plans,"
"contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or
other comparable terminology, although not all forward-looking
statements contain these identifying words. Forward-looking
statements are subject to inherent risks and uncertainties in
predicting future results and conditions that could cause the
actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are
subject to the disclosures set forth in the "Risk Factors" section
of certain of our SEC filings. Forward-looking statements are not
guarantees of future performance, and our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Contact
Kaitlyn Hopkinskhopkins@xbiotech.comTel.
737-207-4600
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024